SUBSCRIBE
SUBSCRIBE

Phase 2

Celgene Cuddles Up With Another Cambridge Biotech, This Time to Tackle Autoimmune Diseases
Drug Development
Top 5 Celgene Drugs With Blockbuster Potential
September 28, 2017
 · 
3 min read
Drug Development
Why Drugmakers Do Interim Clinical Trials
September 26, 2017
 · 
1 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Drug Development
3 Biotechs With Make-or-Break Trial Results, FDA Meetings Coming Soon
September 22, 2017
 · 
3 min read
Drug Development
Who Will Win The Kidney Cancer Battle Between Bristol-Myers Squibb And Exelixis?
September 15, 2017
 · 
1 min read
Why Booming Vertex is on Its Way to Becoming Gilead's Mini-Me
Drug Development
Vertex’s Terminated Phase II CF Trial Was Planned
September 12, 2017
 · 
2 min read
Celgene Cuddles Up With Another Cambridge Biotech, This Time to Tackle Autoimmune Diseases
Drug Development
FDA Orders 6 Partial or Full Clinical Holds on Celgene’s Blood Cancer Studies
September 7, 2017
 · 
2 min read
Bristol-Myers Squibb's Stock Topples as Kidney Cancer Drug Flunks Phase III Study
Drug Development
FDA Slaps Partial Hold on 3 of Bristol-Myers Squibb’s Opdivo-Based Combo Trials
September 7, 2017
 · 
3 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Drug Development
Patient Death Forces Alnylam to Suspend Dosing in Hemophilia Trial, Stock Plunges
September 7, 2017
 · 
2 min read
AstraZeneca PLC Offloads Remaining Anesthetics Portfolio in $766 Million Deal
Drug Development
Investors Wait with Bated Breath for AstraZeneca PLC’s Cancer Trial Data Next Week
September 1, 2017
 · 
3 min read
Incyte Discloses Promising New Data in Combo Drug Trial With Merck & Co.'s Keytruda
Drug Development
Incyte Discloses Promising New Data in Combo Drug Trial With Merck & Co.'s Keytruda
August 31, 2017
 · 
3 min read
Load More
PRESS RELEASES
Press Releases
MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
May 6, 2026
 · 
2 min read
Press Releases
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
May 6, 2026
 · 
14 min read
Press Releases
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients
May 6, 2026
 · 
5 min read
Press Releases
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
May 6, 2026
 · 
15 min read
Press Releases
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
May 6, 2026
 · 
10 min read
Press Releases
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
May 6, 2026
 · 
6 min read
Press Releases
Nocion Therapeutics Announces Full Enrollment in Phase 2b ASPIRE Study of Taplucainium for Chronic Cough
May 5, 2026
 · 
3 min read
Press Releases
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
May 5, 2026
 · 
8 min read
Press Releases
Neuraly, Inc. Supports Phase 2 Investigator-Initiated Trial of Pegsebrenatide (NLY01) for Progressive Multiple Sclerosis
May 5, 2026
 · 
3 min read
Press Releases
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
May 5, 2026
 · 
19 min read
Press Releases
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
May 5, 2026
 · 
17 min read
Press Releases
Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update
May 5, 2026
 · 
8 min read
Press Releases
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
May 5, 2026
 · 
6 min read
Press Releases
Altesa BioSciences Enrolls First Patient in Phase 2b CARDINAL Clinical Trial Evaluating Vapendavir as Transformational Treatment for Patients with COPD Impacted by Rhinovirus, the Leading Cause of Exacerbations
May 5, 2026
 · 
4 min read
Press Releases
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
May 5, 2026
 · 
11 min read
Press Releases
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
May 5, 2026
 · 
9 min read
Press Releases
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
May 5, 2026
 · 
14 min read
Press Releases
Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD)
May 5, 2026
 · 
8 min read
Press Releases
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
May 4, 2026
 · 
4 min read
Press Releases
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
May 4, 2026
 · 
7 min read
Load More